Latest Contractual Agreements News

ARN Media is confronting a substantial legal claim from former contractor Jacqueline Henderson, who alleges adverse action and bullying following her contract termination. The case also challenges previous ASX disclosures, with compensation sought exceeding $82 million.

Brisbane Broncos Limited has reported a robust 2025 financial year, with profit before tax soaring 35% to $11.34 million, buoyed by premiership wins in both the NRL and NRLW competitions. The club also declared a special dividend, reflecting its strong commercial and community momentum.

Legacy Iron Ore Limited reported a positive operating cash flow for Q3 2025, boosting its cash reserves to over A$10 million, supported by ongoing service agreements and the conclusion of a major infrastructure deal.

Austral Resources Australia has locked in $40 million through a discounted share placement, setting the stage for its ASX reinstatement and ambitious expansion in Queensland's copper belt.

Swoop Holdings reported a 19.8% increase in revenue to $106.5 million for FY25, driven by organic growth and new contracts, but posted a wider net loss of $6.95 million. The company is reshaping its portfolio with divestments and major fibre network projects in Greater Melbourne.

Lakes Blue Energy has resumed drilling at its Wombat-5 well in Victoria’s Gippsland Basin, overcoming earlier technical setbacks with a fresh contractor agreement. The company is making solid progress toward its target formation under a fixed price contract.

West Coast Silver Limited has responded to an ASX query about recent share price and volume spikes, confirming no undisclosed material information and providing an update on its ongoing exploration assay program.

ClearVue Technologies and LandGlass subsidiary LandVac have entered a strategic partnership to co-develop and commercialize advanced solar vacuum insulated glazing products, aiming to revolutionize energy-efficient building materials worldwide.

Botanix Pharmaceuticals has initiated the commercial rollout of Sofdra, its FDA-approved treatment for primary axillary hyperhidrosis, with first prescriptions dispensed and a fully trained sales force deployed. The company anticipates meaningful revenue growth starting in the first quarter of 2025, backed by strong payer contracts and a robust cash position.